Type of Study:
Vaccine
Study Length:
~18 months
Target Age/Sex:
Male or Female Infants 42-98 days old
Benefits:
Participants will receive at no cost: Study product an standard of care vaccines, study visits, and study specific procedures. Participants may also receive compensation for their time and travel
Status: Enrolling
Description:
A vaccine trial comparing Prevnar 20 to Prevnar 20+5 which includes 5 addition strains of pneumonia following the CDC guidelines for vaccination schedule.
Privacy Policy: Participants agree to receive text messages from Rosemark Womencare Specialist Clinical Research sent from (208) 487-4999. Message frequency varies and may include text similar to the following: Appointment reminders, service or order information, etc. Message and data rates may apply. Reply STOP at any time to end or unsubscribe. For assistance, reply HELP or contact support at: (208) 557-2924
See our Privacy Policy for details on how we handle your information